IP Library Patent Application 13748017
Patent Application
App. No. 13/748,017

Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/748,017
Abstract

This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).

Claims (26)

1 . An expression system to provide extended episomal replication of hybrid plasmid in eukaryotic cell lines, said system comprising:

a) a vector comprising a polyoma virus core origin according to SEQ ID NO:2, an FR element of EBV, a selection marker, and a gene of interest operably linked within an expression cassette expressing the gene in a eukaryotic cell; and

b) a compatible mammalian cell line, where the vector is expressed, said cell line constitutively expressing EBV EBNA1 protein and PyV LT protein either in presence or in absence of selective pressure.

2 . The system according to claim 1 , wherein the FR element comprises at least 21 EBNA1 binding sites.

3 . The system according to claim 2 , wherein the EBNA 1 binding sites are according to sequences selected from the group consisting of SEQ ID NOs: 3, 4, and 6.

4 . The system according to claim 3 , wherein the FR element is according to SEQ ID NO:1.

5 . The system according to claim 1 , wherein the cell line is of mouse, hamster or human origin.

6 . The system according to claim 1 , wherein the gene of interest encodes a protein for pharmaceutical use.

7 . The system according to claim 6 , wherein the protein is a monoclonal antibody.

8 . The system according to claim 6 , wherein the protein is virus envelope or capside protein.

9 . The system according to claim 6 , where the protein is fused to an epitope-tag.

10 . The system according to claim 9 , where the epitope tag has an amino acid sequence selected from the group consisting of SEQ ID NO:20, 21, 22 and 23.

11 . An expression plasmid for use in a mammalian cell expression system, said vector comprising:

a) a polyoma virus core origin,

b) an FR element of Eppstein Barr Virus (EBV);

c) a selection marker; and

d) an expression cassette for expression a gene of interest in a eukaryotic cell.

12 . The expression plasmid of claim 11 , where the polyoma virus core origin is according to SEQ ID NO:2 and the FR element is according to SEQ ID NO:1.

13 . The expression plasmid of claim 11 , wherein the expression cassette comprises a multicloning site for insertion of the gene of interest, and a promoter.

14 . The expression plasmid of claim 13 , wherein the promoter is selected from the group consisting of Cytomegalovirus immediate early (CMV)-promoter, EF1α; EF1α-HTLV, heIF 4a, β-actine, and Rous Sarcoma Virus proviral Long Termina Repeat (RSV-LTR)-promoter.

15 . The expression plasmid of claim 13 , wherein the gene of interest encodes a protein for pharmaceutical use.

16 . The expression plasmid of claim 15 , wherein the protein is a monoclonal antibody.

17 . The expression plasmid of claim 15 , wherein the protein is virus envelope or capside protein.

18 . The expression plasmid of claim 15 , where the protein is fused to an epitope-tag.

19 . The expression plasmid of claim 18 , where the epitope tag has an amino acid sequence selected from the group consisting of SEQ ID NO:20,21,22, and 23.

20 . A cell lien comprising the expression plasmid of claim 11 .